Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
DURHAM, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company...
-
DURHAM, N.C., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases...
-
Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter net product sales of...
-
Third quarter net product sales of $2.9 million from DOPTELET® (avatrombopag); 335 cumulative unique prescribers from launch through September 30, 2018 sNDA accepted for review by FDA for DOPTELET...
-
DURHAM, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that the management team will present a company overview at four upcoming investor...
-
DURHAM, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases...
-
DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Thursday, November 8, 2018 at 4:30 p.m. ET to discuss third quarter 2018...
-
DURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), please note...
-
DURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and...
-
DURHAM, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...